Noémi De Wispelaere, Sebastian Dwertmann Rico, Marcus Bauer, Andreas M Luebke, Martina Kluth, Franziska Büscheck, Claudia Hube-Magg, Doris Höflmayer, Natalia Gorbokon, Sören Weidemann, Katharina Möller, Christoph Fraune, Christian Bernreuther, Ronald Simon, Christian Kähler, Anne Menz, Andrea Hinsch, Frank Jacobsen, Patrick Lebok, Till Clauditz, Guido Sauter, Ria Uhlig, Waldemar Wilczak, Stefan Steurer, Eike Burandt, Rainer Krech, David Dum, Till Krech, Andreas Marx, Sarah Minner
p16 (CDKN2A) is a member of the INK4 class of cell cycle inhibitors, which is often dysregulated in cancer. However, the prevalence of p16 expression in different cancer types is controversial. 15,783 samples from 124 different tumor types and 76 different normal tissue types were analyzed by immunohistochemistry in a tissue microarray format. p16 was detectable in 5,292 (45.0%) of 11,759 interpretable tumors. Except from adenohypophysis in islets of Langerhans, p16 staining was largely absent in normal tissues...
2022: PloS One